Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Billiontoone Inc. currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 3 pending office actions are spread across 2 distinct art units, suggesting a relatively focused portfolio that nonetheless touches on different specialized areas of biotechnology. The use of 2 distinct art units means that the company's applications are being evaluated by at least two different groups of experts at the patent office. Practitioners must be prepared to address the specific standards of each of the distinct art units.
The 3 pending office actions are being reviewed by 3 distinct examiners. This indicates that each of the pending office actions is being handled by a different individual, providing a variety of examiner perspectives. VANORE, DAVID A is the busiest examiner for the portfolio, currently overseeing 1 pending office action. Since there are 3 distinct examiners for the 3 pending office actions, each examiner is responsible for exactly one pending action. This distribution requires the legal team to manage three separate prosecution tracks simultaneously.
Practitioners should be aware that the 3 pending office actions are distributed across the art units and examiners. This means that while there may be some overlap in art unit standards, the individual examiner styles will vary for each case. VANORE, DAVID A and the other examiners each hold 1 pending office action, requiring the legal team to manage separate prosecution tracks within the Biotechnology & Pharmaceuticals sector. Success depends on coordinating efforts across the 2 distinct art units while respecting the unique approach of each of the 3 distinct examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VANORE, DAVID A | 1 | 88.9% | +7.5% |
| ZHANG, KAIJIANG | 1 | 77.1% | +34.4% |
| CASH, KAILEY ELIZABETH | 1 | 28.6% | +64.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18943785 | TARGET-ASSOCIATED MOLECULES FOR CHARACTERIZATION ASSOCIATED WITH BIOLOGICAL TARGETS | VANORE, DAVID A | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17702708 | FRAGMENT ANALYSIS FOR QUANTITATIVE DIAGNOSTICS OF BIOLOGICAL TARGETS | CASH, KAILEY ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17952098 | QUALITY CONTROL TEMPLATES ENSURING VALIDITY OF SEQUENCING-BASED ASSAYS | ZHANG, KAIJIANG | — |
| 17702708 | FRAGMENT ANALYSIS FOR QUANTITATIVE DIAGNOSTICS OF BIOLOGICAL TARGETS | CASH, KAILEY ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18943785 | TARGET-ASSOCIATED MOLECULES FOR CHARACTERIZATION ASSOCIATED WITH BIOLOGICAL TARGETS | VANORE, DAVID A | — | §112 | Non-Final OA | — | Pending | Nov 11, 2024 |
| 17952098 | QUALITY CONTROL TEMPLATES ENSURING VALIDITY OF SEQUENCING-BASED ASSAYS | ZHANG, KAIJIANG | 1684 | §102 | Non-Final OA | — | Pending | Sep 23, 2022 |
| 17702708 | FRAGMENT ANALYSIS FOR QUANTITATIVE DIAGNOSTICS OF BIOLOGICAL TARGETS | CASH, KAILEY ELIZABETH | 1683 | §103§112DP | Final Rejection | — | Pending | Mar 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial